AZNAstraZenecaRunning, no new patients
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Small Cell Lung Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 71 (final count)
- Started
- Sep 15, 2025
- Main results expected
- Jun 30, 2029
- Fully finished
- Jun 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To describe the safety profile of durvalumab for patients with LS-SCLC who have not progressed following CRT.
Measured over: 90 days after last dose of durvalumab of the last patient.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06992609 · record last updated 2026-10-26 · checked 2026-11-09 15:47 UTC